Rankings
▼
Calendar
URGN Q2 2017 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena
URGN
UroGen Pharma Ltd.
$918M
Q2 2017 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$6M
Net Income
-$6M
EPS (Diluted)
$-0.67
QoQ Revenue Growth
-100.0%
Cash Flow
Operating Cash Flow
-$3M
Free Cash Flow
-$3M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$79M
Total Liabilities
$5M
Stockholders' Equity
$74M
Cash & Equivalents
$77M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$6M
-$3M
-75.3%
Net Income
-$6M
-$3M
-86.9%
← FY 2017
All Quarters
Q3 2017 →